Drugs / PELTOPEPIMUT-S
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02128126 | Sep 2013 → Aug 2018 | cervical cancer | ISA Pharmaceuticals | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT04398524 | Jul 2021 → Jun 2024 | oropharynx squamous cell carcinoma | ISA Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT04646005 | Jun 2021 → May 2023 | cervical cancer | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04369937 | Jul 2020 → Mar 2025 | head and neck squamous cell carcinoma, human papillomavirus-related squamous cell carcinoma | Dan Zandberg | Completed | No outcome recorded |
| Phase 2 | NCT03669718 | Nov 2018 → Sep 2024 | human papillomavirus-related squamous cell carcinoma, oropharynx squamous cell carcinoma | ISA Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT03258008 | Apr 2018 → Nov 2021 | cancer of unknown primary site, oropharynx squamous cell carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PELTOPEPIMUT-S | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095477 ↗ |
| Known as | ISA101b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02128126 ↗ |
| Modality | Vaccine | “ISA101/ISA101b is a novel therapeutic synthetic long peptide (SLP) vaccine targeting HPV16” NCT02128126 ↗ |
| Route | Subcutaneous | “ISA101b 100 mcg/peptide given subcutaneously” NCT03258008 ↗ |